

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (allowed) A method for modulating angiogenesis comprising introducing a zinc finger protein into an animal having a genome comprising a target site within a vascular endothelial growth factor (VEGF) gene, whereby the zinc finger protein binds to the target site and thereby modulates angiogenesis in the animal, wherein the zinc finger protein binds to a target site specified in Table 3 (SEQ ID NOS: 1-29 and 244) or Table 4 (SEQ ID NOS: 117-119).
2. (currently amended) The method according to claim 1, wherein positions -1 to +6 in each of three zinc fingers are occupied by first (SEQ ID NOS: 30-58), second (SEQ ID NOS: ~~69-87~~ 59-87, 112, and 245-252) and third segments (SEQ ID NOS: 42, 68 and 88-116) of seven contiguous amino acids as specified in a row of Table 3.
3. (currently amended) The method according to claim 1, wherein the zinc finger protein comprises six zinc fingers, and positions -1 to +6 in each of the six zinc fingers are occupied by first (SEQ ID NOS: ~~117-119~~120-122, ~~120-122~~123-125), second (SEQ ID NOS: ~~123-125~~126-128, ~~126-128~~129-131), fifth (SEQ ID NOS: ~~129-131~~132-134) and sixth (SEQ ID NOS: ~~132-134~~135-137) segments of seven contiguous amino acids as specified in a row of Table 4.
4. (allowed) The method according to claim 1, wherein the target site is present in a plurality of VEGF genes, whereby the zinc finger protein binds to the target site in the plurality of genes, thereby modulating expression of the plurality of VEGF genes.
5. (allowed) A method of treating ischemia, comprising administering a zinc finger protein that binds to a target site within a VEGF gene into an animal having ischemia, wherein the animal has a genome comprising a VEGF gene comprising the target site and the zinc finger protein binds to the target site, and wherein the zinc finger protein is administered in an amount

Amtd. dated November 19, 2005

Response to Notice of Allowance September 22, 2005

effective to treat ischemia, wherein the zinc finger protein binds to a target site specified in Table 3 (SEQ ID NOS: 1-29 and 244) or Table 4 (SEQ ID NOS: 117-119).

6. (currently amended) The method according to claim 5, wherein positions -1 to +6 in each of three zinc fingers are occupied by first (SEQ ID NOS: 30-58), second (SEQ ID NOS: ~~69-87 59-87~~, 112, and 245-252) and third segments (SEQ ID NOS: 42, 68 and 88-116) of seven contiguous amino acids as specified in a row of Table 3.

7. (currently amended) The method according to claim 5, wherein the zinc finger protein comprises six zinc fingers, and positions -1 to +6 in each of the six zinc fingers are occupied by first (SEQ ID NOS: ~~117-119~~120-122), second (SEQ ID NOS: ~~120-122~~123-125), third (SEQ ID NOS: ~~123-125~~126-128), fourth (SEQ ID NOS: ~~126-128~~129-131), fifth (SEQ ID NOS: ~~129-131~~132-134) and sixth (SEQ ID NOS: ~~132-134~~135-137) segments of seven contiguous amino acids as specified in a row of Table 4.

8. (allowed) The method of claim 5, wherein the zinc finger protein is applied to a specific tissue of the animal.

9. (allowed) The method according to claim 5, wherein the zinc finger protein comprises at least three fingers of the C2H2 class of zinc fingers.

10. (allowed) A method for treating a wound comprising introducing a zinc finger protein into an animal having a genome comprising a target site within a VEGF gene, whereby the zinc finger protein binds to the target site, such binding accelerating healing of the wound, and wherein the zinc finger protein binds to a target site specified in Table 3 (SEQ ID NOS: 1-29 and 244) or Table 4 (SEQ ID NOS: 117-119).

11. (currently amended) The method according to claim 10, wherein positions -1 to +6 in each of three zinc fingers are occupied by first (SEQ ID NOS: 30-58), second (SEQ ID NOS: ~~69-87 59-87~~, 112, and 245-252) and third segments (SEQ ID NOS: 42, 68 and 88-116) of seven contiguous amino acids as specified in a row of Table 3.

12. (currently amended) The method according to claim 10, wherein the zinc finger protein comprises six zinc fingers, and positions -1 to +6 in each of the six zinc fingers are

Amdt. dated November 19, 2005

Response to Notice of Allowance September 22, 2005

occupied by first (SEQ ID NOS: ~~117-119~~120-122), second (SEQ ID NOS: ~~120-122~~123-125), third (SEQ ID NOS: ~~123-125~~126-128), fourth (SEQ ID NOS: ~~126-128~~129-131), fifth (SEQ ID NOS: ~~129-131~~132-134) and sixth (SEQ ID NOS: ~~132-134~~135-137) segments of seven contiguous amino acids as specified in a row of Table 4.

13. (allowed) The method of claim 10, wherein the zinc finger protein is applied topically.